Bitter Sweet Symphony? Indian Patent Office Rejects BPaL Patent Application in an Unreasoned Order

Album artwork for The Verve’s Bitter Sweet Symphony. The cover features a split-panel design, with a green-tinted urban street scene on the left and a close-up image of a person covering their mouth on the right, alongside the album title and track information.
Image from here

The Indian Patent Office on October 27 rejected (pdf) the Global Alliance for TB Drug Development Inc.’s (TB Alliance) patent application for a combination BPaL regimen comprising bedaquiline, pretomanid, and linezolid. The regimen is used to treat a type of multidrug-resistant tuberculosis, which is a major problem in India, with the country accounting for 32% of global cases. After two rounds of amendments, the TB Alliance’s claimed invention was a unitary dosage form (i.e. a single, physically identifiable unit like a capsule or a tablet) containing the three drugs in defined quantities. In the First Examination Report and then in two separate Pre-Grant Oppositions (PGOs) (filed by Eldred Tellis and Ganesh Acharya, and the Delhi Network of Positive People, respectively), the application was opposed on, inter alia, grounds of lack of novelty and inventive step, lack of enablement, non-patentability under Section 3(e) and Section 3(i).

Interestingly, the TB Alliance amended the claims after these PGOs but, right before the hearing, it refused to appear before the Controller, requesting the Indian Patent Office (IPO) to instead decide the application based on the material available on record. Consequently, in a very short order, the patent application was rejected by the patent office.

While the world is celebrating this as a victory (that it is) for wider access to medicines (see here, and here), there is perhaps still reason for concern. The order is extremely short on reasons for why the application was rejected. The 3-page order merely summarises the grounds for opposition, briefly explains the invention, and then states that “Upon consideration of the representations filed by both the Opponents, the documents on record, the cited prior art and the submissions available on record, the grounds of opposition….still stands and found valid.” without explaining further. This (lack of) explanation becomes crucial in light of the fact that the claims were already amended based on the objections in the FER and the grounds of opposition raised. In this post, I’ll take a look at why this is an important consideration and also assess whether the amended claims could have overcome the objections/ grounds of opposition.

Understanding the Regimen

Before we get to the order, let me try to explain a bit about why the regimen is remarkable. Earlier, as explained by Mercy and Babu, the standard of care for Multi Drug ResistantR-TB would fall under 2 options– a shorter regimen (9–11 months), which was unsuitable for patients with fluoroquinolone resistance, and longer regimens (18–24 months) involving injectable drugs associated with serious, sometimes irreversible side effects. Both approaches suffered from poor treatment outcomes, high loss-to-follow-up rates, significant adverse effects, and substantial financial burdens on patients and their families, highlighting the need for safer, more effective, and patient-centric treatments.

Following evidence from clinical trials such as Nix-TB (which is one of the cited prior art in the present case), ZeNix, and TB-PRACTECAL, the WHO’s 2022 guidelines recommended the six-month, all-oral BPaLM regimen for MDR/RR-TB and the BPaL regimen for pre-XDR-TB. These regimens marked a significant shift from the earlier 18-24 month treatment approaches to just 6-month regimens, promising better adherence, reduced toxicity, and improved treatment outcomes.

A bit on the Prosecution History

As mentioned, the claimed invention was a unitary dosage form containing the three drugs in defined quantities. This was an amendment over the previous claims, which were over a broadly defined pharmaceutical combination. On the initial set of claims, the FER as well as both the PGOs stated that the invention was not new and was obvious. For this, they relied on prior art documents including a Phase 3 study assessing the safety and efficacy of Bedaquiline, Pretomanid, Linezolid in subjects with DR-TB (“Archive History for NCT02333799” and a study on a regimen for treatment of extensively drug-resistant pulmonary tuberculosis (“Nix-TB: Testing a New Potential Treatment for XOR-TB”) The application was also opposed on other grounds, notably that the invention does not show any synergistic effects and is a method of treatment and is thus barred under Section 3(e) and Section 3(i), respectively, and that the complete specification does not sufficiently disclose the invention.

Issues with the Order

In the summary refusal, the order also noted that the TB Alliance chose not to submit oral arguments in support of the patentability. However, the TB Alliance, in its representation dated October 12 (pdf), refused to appear for the hearing and requested the Patent Office to decide the matter based on the documents available on the record, which included its complete specification, reply to the FERs, replies to the PGOs, and the amended claims after the PGOs and a reply to the rejoinder filed by the Delhi Network of Positive People.

In their last set of amendments, the applicant had made some major changes in the claims, such as changing the invention from a broadly defined pharmaceutical combination to a unitary dosage form (more on this below). Therefore, it becomes imperative that the IPO explains how these developments in the course of the prosecution journey would affect or would not affect the grounds of objections/ oppositions raised above. Most significantly, the lack of reasons gives an easy basis for appeal, as High Courts have repeatedly shown! In the past, we have recorded numerous instances of why the orders from the Patent Office need to be reasoned and how they contribute towards a more robust and accountable IP system in the country. In this case as well, after making substantive amendments to the claims, a reasoned order rejecting the application would have set the right precedent for future cases where, on the one hand, the officers can learn from how the law is to be interpreted in similar situations and on the other hand, the public at large could see the patent laws and principles in action.

It is also important to note that passing a detailed order becomes important procedurally here, since one of the Opponents filed a “Rejoinder” against the Reply to the Opposition. Neither the Patent Act nor the Patent Rules allow for filing a rejoinder, although the Rules do allow for filing “evidence” after the applicant’s reply within one month from the date of its delivery (Rule 59). So, did the IPO regard this rejoinder as evidence under Rule 59, or did it accept it as a rejoinder? Clarity on this would throw light on how the IPO takes into account the Patent Rules and may affect cases in the future as well.

(A side note here is that from the set of documents available on the IP India website and on a reading of the IPO Order, it’s not clear that a hearing in fact actually took place. After the TB Alliance’s refusal, the two opponents also asked for an adjournment and specified that the relevant fees have been paid by them. However, neither a new notice of hearing nor any mention of a hearing is in the IPO order.)

Have the Amended Claims Overcome the Grounds of Opposition?

In my understanding of the amended claims, complete specifications, and the PGOs, even if reasons had been given, would not have changed the outcome. I think it would still have been an uphill task for the TB Alliance to overcome the grounds of the opposition and the objection raised by the patent office in the FER. The difference between the last set of amendments and the earlier claims has been reproduced below:-

AspectEarlier claims after the FER (1–6)Amended claims after PGOs (1–11)
Nature of compositionA pharmaceutical composition containing therapeutically effective amounts of the drugs.A pharmaceutical composition specifically in a unitary dosage form
Composition of drugsLinezolid, bedaquiline and pretomanid, optionally with pyrazinamide.The antibacterial agents are expressly limited to linezolid, bedaquiline and pretomanid, with pyrazinamide as an optional addition.
Dosage requirementsGenerally claimed therapeutically effective amounts, with specific linezolid dosages in claims 2 (100 mg/kg) and 3 (50 mg/kg).Each of the three drugs must be present in the unitary dosage form in an amount of 1 mg to 1 g.
Individual drug quantitiesClaim 5 specified 600/1200 mg linezolid, 200–400 mg bedaquiline and 100–200 mg pretomanid collectively across multiple dosage units.Separate claims specify 200–400 mg bedaquiline, 600 mg linezolid and 100–200 mg pretomanid in the unitary dosage form.
Dosage formCould be a single or multiple dosage units.Specifically limited to a unitary dosage form, with claim 7 identifying tablets or capsules.

From the above, it can be seen that the amended claims focus on a unitary dosage form, specifying the absolute quantities of individual drugs. The more specific formulation and dosage limitations in one way may distinguish the claimed invention from the cited prior art documents, which disclosed the BPaL treatment regimen, the dosage strength, and their administration, but do not disclose a single tablet or capsule containing all three drugs together. These amendments can also be traced to the complete specification (pdf) where the applicant disclosed that the combination may be formulated in a unit-dose formulation comprising a fixed amount of each active pharmaceutical ingredient.

At the same time, it is to be noted that the specification’s formulation discussion is largely general and does not give any working examples of a tablet or a capsule containing the drugs in the claimed amount. Instead, the given examples demonstrate the efficacy of the combination as treatment regimens rather than the preparation or performance of a single co-formulated dosage. In the past, we have seen courts taking a more conservative approach towards working examples vis-à-vis the scope of patents; Dhruv has made a compelling case for seeing working examples while assessing sufficiency of disclosure. In the absence of such working examples, it remains open whether a person skilled in the art could prepare the claimed compositions across the wide dosage ranges, without undue experimentation.

Another issue that the amendments, the complete specification and the applicant’s response to the FER do not appear to fully overcome is the objection under Section 3(e). In response to the FER, the applicant has argued that the combination produces a synergistic effect, particularly through the sterilising activity contributed by linezolid. The specification does contain experimental data indicating enhanced antibacterial and sterilising activity from combinations involving linezolid, bedaquiline and pretomanid, making it difficult to argue that there is no evidence of synergy. However, the experimental data relate to the therapeutic activity of the drugs as a treatment regimen and not their physical co-formulation into a single dosage form. Therefore, the question remains whether the evidence sufficiently establishes the claimed synergistic effect across the full breadth of the amended claims, which cover wide dosage ranges and the optional inclusion of pyrazinamide, and presently the required explanation seems to be missing from the applicant’s end.

Overall, the case sets a great example of how the safeguards in the Indian Patent Act operate and explains (yet again) why oppositions are a crucial tool at the service of the officers at the IPO; the lack of an unsubstantiated order does make the warning bells ring, considering the overall impact it can have on how applications are heard and eventually adjudicated upon by the IPO.

[Thanks to Swaraj Paul Barooah for his comments on the post and to Priyam Cherian and Sandeep Rathod for their inputs and discussion leading up to this post. Priyam was one of the lawyers who represented the opponents in the early stages of the first pre-grant opposition, while Sandeep also provided valuable inputs on the opposition.]

Tags: , , , , , ,

Leave a Comment

Scroll to Top